Forgot your password?

Forgot your username?

database > company
Atrix Laboratories
Biotech Specialty Pharma
2579 Midpoint Drive
Fort Collins, CO 80525 USA
phone:604.707.7000
fax:604.707.7001
Symbol QLT
Exchange NASDAQ
Founded 0
Employees
www.atrixlabs.com
Research Sector Biotech Specialty Pharma
Summary Description
Specialty pharmaceutical company focused on advanced drug delivery.
Management
Robert Butchofsky, President and Chief Executive Officer; Alain Curaudeau, Senior Vice President, Portfolio and Project Management; Therese Hayes, Vice President, Investor Relations and Corporate Communications; Linda Lupini, Senior Vice President, Human Resources and Organizational Development; Alexander Lussow, Vice President, Business Development; Cameron Nelson, Vice President, Finance and Chief Financial Officer; Peter J. O'Callaghan, Senior Vice President, Corporate Development and General Counsel; Daniel Wattier, Vice President, Marketing and Sales
 

Keywords
drug delivery, dermatology, pain management, oncology, PainManagement, DrugDelivery



Comment | Printable Version | Modify profile |
Updated: Jun. 27, 2012

Description

Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company focused on advanced drug delivery. Atrix has successfully applied its Atrigel drug formulation technology to introduce 1-month,...

view more
Products / Services
The company's lead product is Eligard, a long-acting injectable formulation of leuprolide acetate for the treatment of prostate cancer that has been partnered in the US with Sanofi-Synthelabo. Another near-term opportunity is Atrisone, a topical dermatology product (dapsone for acne) in late Phase III development that is being developed in collaboration with Fujisawa.
Technology / Differentiation
With five unique patented technologies, Atrix is currently developing a diverse portfolio of proprietary products, including oncology, pain management and dermatology products. The company also partners with large pharmaceutical and biotechnology companies to apply its proprietary technologies to new chemical entities or improve existing products


2013-06-18-3713